NCT07459296 2026-03-16
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
First Affiliated Hospital of Guangxi Medical University
Phase 3 Recruiting
Clinical Trials
10 trialsNCT06900218 2025-04-02
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06680115 2024-11-08
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
First Affiliated Hospital of Guangxi Medical University
Phase 2 Not yet recruiting
NCT06364826 2024-04-15
Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT04072107 2023-06-18
EP-STAR
Sun Yat-sen University
Phase 2 Unknown
NCT04872582 2023-02-23
Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study
Sun Yat-sen University
Phase 2 Unknown
NCT05707819 2023-02-01
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Cancer Hospital of Guangxi Medical University
Recruiting
NCT05201859 2022-05-06
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04917770 2021-06-08
The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
West China Hospital
Phase 2 Unknown
NCT04769076 2021-02-25
The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown